SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1365-1370. doi: 10.15585/mmwr.mm7251a2.ABSTRACTRebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease ...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Patrick R Harrington Jie Cong Stephanie B Troy Jonathan M O Rawson Julian J O'Rear Thamban Illath Valappil Sarah McGarry Connelly John Farley Debra Birnkrant Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin
ConclusionAtorvastatin doses should likely be adjusted during nirmatrelvir/ritonavir treatment. For patients on a 20-mg dose, we recommend half of the original dose. In patients taking 40 mg or more, a quarter of the dose should be taken until 2 days after discontinuation of nirmatrelvir/ritonavir. Patients receiving rosuvastatin do not need to change their treatment regimen.Trial RegistrationEudraCT number: 2021 –006634-39.DRKS00027838. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - December 19, 2023 Category: Cardiology Source Type: research
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
ConclusionAvailable evidence about the effect of medication treatment with antivirals during acute COVID-19 and reduced risk of developing long-COVID is conflicting. Heterogeneous evidence suggests that Remdesivir or Nirmaltrevir/Ritonavir could have a potential protective effect for long-COVID. A limited number of studies demonstrated a potential benefit of other medications such as Dexamethasone or Metformin, but more studies are needed. (Source: Infection)
Source: Infection - December 19, 2023 Category: Infectious Diseases Source Type: research
